ARGONAUT: from the synthesis of gAnglioside tumouR antiGens to a platfOrm for caNcer Active immUnoTherapy

Project description

A novel approach for the development of cancer vaccines

Immunotherapy is a promising approach for treating cancer, but so far, cancer vaccines have demonstrated limited success in clinical trials. Recently, the identification of aberrant tumour-associated carbohydrate antigens (TACAs) on the surface of cancer cells has spurred the development of novel cancer vaccines. The EU-funded ARGONAUT project aims to address the problems associated with the development of effective vaccine candidates through novel technologies. The focus will be on vaccines based on ganglioside-type TACAs that are easy to formulate and can elicit an immune response independent of individual genetic variations. The project will offer the possibility for a more tumour-selective immunotherapy approach.

Fields of science

• medical and health sciences › clinical medicine › oncology › lung cancer
• medical and health sciences › clinical medicine › oncology › skin cancer › melanoma
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• natural sciences › biological sciences › biochemistry › biomolecules › carbohydrates
• medical and health sciences › basic medicine › immunology › immunotherapy

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

DANMARKS TEKNISKE UNIVERSITET

Net EU contribution

€ 207 312,00

Address

Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby
Denmark

Region

Danmark › Hovedstaden › Københavns omegn

Activity type

Higher or Secondary Education Establishments

Links

Other funding

€ 207 312,00